MICHAEL ROBERTSON to Hodgkin Disease
This is a "connection" page, showing publications MICHAEL ROBERTSON has written about Hodgkin Disease.
Connection Strength
0.950
-
A randomized phase 2 study of ipilimumab, nivolumab, and brentuximab vedotin in patients with relapsed Hodgkin lymphoma. Blood. 2026 Apr 30; 147(18):2041-2052.
Score: 0.776
-
Ipilimumab, nivolumab, and brentuximab vedotin combination therapies in patients with relapsed or refractory Hodgkin lymphoma: phase 1 results of an open-label, multicentre, phase 1/2 trial. Lancet Haematol. 2020 Sep; 7(9):e660-e670.
Score: 0.131
-
Phase II clinical trial of interleukin-12 in patients with relapsed and refractory non-Hodgkin's lymphoma and Hodgkin's disease. Clin Cancer Res. 2004 Aug 15; 10(16):5432-8.
Score: 0.043